Skip to main content

Table 4 Demographics and baseline characteristics of patients included in the studies used in the final qualitative synthesis

From: Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review

Study

Previous treatment failures

Anti-CGRP mAb

Mean age

N

Femalea

Mean MMD at baseline

Mean MAMD at baseline

Years since initial migraine diagnosis

MSQ

Ashina et al. NCT 02,066,415 [67]

 ≥ 2

Placebob

42.9 (11.5)

286

78.2%

18.3 (4.5)

11.4 (7.4)

24.0 (12.9)

No data

Erenumab

70 mgb

42.9 (11.2)

191

90.3%

18.0 (4.4)

10.5 (7.2)

25.2 (13.2)

Erenumab

140 mgb

44.2 (10.6)

190

89.1%

18.8 (4.4)

12.4 (7.2)

24.6 (11.7)

Ferrari et al. FOCUS (NCT03308968) [68]

2–4

Placebob

46.8 (11.1)

279

83%

14.3 (6.1)

12.3 (6.3)

24.3 (13.6)

No data

Fremanezumab (quarterly treatment)c

45.8 (11.0)

276

84.1%

14.1 (5.6)

12.8 (6.2)

24.3 (12.8)

Fremanezumab (monthly treatment)d

45.9 (11.1)

283

83.5%

14.1 (5.6)

12.2 (6.0)

24.0 (13.7)

Ruff et al. REGAIN (NCT02614261) [69]

 ≥ 2

Placebob

43.9 (11.8)

558

88.7%

19.6 (4.71)

15.8 (6.0)

24.3 (13.1)

37.5 (17.7)

Galcanezumab 120 mgb

42.8 (11.3)

278

91.9%

20.0 (4.3)

16.6 (5.6)

22.6 (13.3)

39.5 (17.2)

Galcanezumab 240 mgb

42.1 (12.6)

277

82.9%

19.0 (4.9)

14.7 (5.8)

21.3 (13.4)

38.3 (16.9)

Mulleners et al.

CONQUER (NCT03559257) [70]

2–4

Placebob

44.8 (13.1)

98

87%

18.1 (4.7)

16.4 (6.0)

24.9 (14.9)

40.5 (19.7)

Galcanezumab 120 mgb

45.8 (11.6)

95

87%

19.2 (4.7)

16.0 (6.9)

24.2 (13.9)

41.9 (17.0)

  1. Data are presented as mean (SD) unless stated otherwise
  2. Anti-CGRP mAb calcitonin gene-related peptide monoclonal antibodies, MMD monthly migraine days, MAMD, monthly acute migraine-specific medication days, MSQ Migraine-specific Quality of Life Questionnaire, SD, standard deviation, N number of patients
  3. aPercentages represent categorical variables compared to the total number of patients in each treatment subgroup
  4. bMonthly administration for 3 months
  5. cFirst dose consists of fremanezumab 675 mg and placebo in the remaining 2 months
  6. dFirst dose consists of fremanezumab 675 mg followed by monthly fremanezumab 225 mg for 2 months